Browse the evidence

Continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea syndrome (OSAS) significantly reduces in vitro platelet aggregability induced by epinephrine, restoring physiological diurnal patterns.

If you have obstructive sleep apnea, using your CPAP machine consistently every night for at least six months can significantly improve your blood's tendency to clot (platelet aggregability). This is a key mechanism for reducing your risk of heart attacks and strokes associated with sleep apnea. Ensure your device is delivering the prescribed pressure and that you are using it nightly to achieve these cardiovascular benefits.

The PPARδ agonist GW501516 increases glucose uptake in human skeletal muscle cells via an AMPK-dependent mechanism that is independent of PPARδ expression.

This research identifies a specific mechanism by which PPARδ activation improves glucose handling in muscle cells: it bypasses the PPARδ receptor itself to activate AMPK, a key energy sensor. While GW501516 is a research chemical and not a consumer supplement, this finding suggests that strategies which activate AMPK (such as exercise or specific metabolic stressors) may mimic this glucose-uptake benefit independently of PPARδ expression levels.

The PPARδ agonist GW501516 increases fatty acid oxidation in human skeletal muscle through a mechanism that requires both PPARδ expression and functional AMPK.

This study shows that maximizing fat oxidation in muscle cells requires both PPARδ and AMPK to be active. While GW501516 is not a consumer product, this suggests that natural methods activating both pathways (like high-intensity exercise which activates AMPK and can upregulate PPARδ over time) are synergistic for lipid metabolism.

Metformin administration is associated with a reduced incidence of multiple age-related diseases and all-cause mortality in both diabetic and non-diabetic populations.

If you are taking metformin for diabetes, you may already be benefiting from reduced risks of age-related conditions. For non-diabetics considering metformin for longevity, the evidence is promising but not yet definitive (TAME trial pending). Discuss with your doctor, especially regarding kidney function and potential side effects like GI distress, which can often be managed with dosing strategies.

Metformin treatment improves outcomes in osteoarthritis (OA) by reducing inflammation, protecting articular cartilage via the AMPK pathway, and reducing body weight.

For those with osteoarthritis, especially if overweight, metformin (if prescribed for diabetes) may offer additional joint protection and pain relief. This is likely due to its anti-inflammatory properties and weight loss effects. Consult your doctor about whether existing metformin therapy is contributing to joint health.

Metformin use is associated with a reduced risk of various cancers, including breast, colorectal, and pancreatic cancer, though effects on pancreatic cancer prognosis are mixed.

If you have diabetes and take metformin, you may have a lower risk of developing certain cancers like breast and colorectal cancer. However, it is not a cancer treatment itself. Do not stop taking metformin to 'prevent' cancer without consulting your doctor, as the benefits for diabetes management are primary.

Chronic cold exposure induces white-to-brown adipocyte transdifferentiation, increasing energy expenditure and protecting against obesity and type 2 diabetes.

Exposure to cold temperatures can trigger your body to convert energy-storing white fat into energy-burning brown-like fat (beige fat). This process increases your metabolic rate and helps protect against obesity and type 2 diabetes. While you don't need to freeze yourself, understanding this mechanism highlights the importance of factors like exercise (which releases irisin) and potentially cold exposure in managing metabolic health. Future treatments may target these pathways pharmacologically.

A single bout of heavy resistance exercise transiently elevates mRNA levels of myogenic regulatory factors (myogenin, MyoD, MRF4) in human skeletal muscle, suggesting their involvement in regulating hypertrophy and fiber-type transitions.

Performing heavy resistance training triggers immediate genetic signals in your muscles that help build size and change fiber types. You do not need to optimize anything other than performing the exercise with sufficient intensity (heavy loads) to trigger this response. The body's molecular machinery handles the rest during recovery.

A single bout of heavy resistance exercise decreases the mRNA content of the IGF-IEa isoform during the initial recovery phase (1-6 hours), while the MGF (IGF-IEc) isoform remains unaffected.

After heavy lifting, your body temporarily reduces the production of one specific type of IGF-I (IGF-IEa) in the first few hours, while maintaining the muscle-specific version (MGF). This is a normal part of the body's regulatory process and does not mean your muscle-building potential is compromised. Focus on consistent training rather than worrying about immediate molecular fluctuations.

Treatment with omega-3 polyunsaturated fatty acids (specifically EPA and DHA) suppresses macrophage inflammation by activating the AMPK/SIRT1 pathway, which deacetylates the NF-kB subunit p65 and inhibits its signaling.

This research explains the biological mechanism behind why omega-3s (EPA/DHA) are considered anti-inflammatory: they activate cellular energy sensors (AMPK/SIRT1) that turn off inflammatory signals (NF-kB). While this is a cellular study, it supports the general recommendation of omega-3s for managing inflammation, particularly in the context of metabolic health.

Higher circulating levels of phospholipid metabolites, specifically choline, glycerophosphoethanolamine, and glycerophosphorylcholine (GPC), are associated with an insulin-sensitive phenotype in obese individuals, distinguishing them from obese insulin-resistant individuals.

This research suggests that for obese individuals, metabolic health (specifically insulin sensitivity) can be distinguished by blood levels of choline and related phospholipids. Higher levels of these metabolites are linked to a protective, insulin-sensitive state. This implies that metabolic health is not uniform across all obese individuals and may be assessed through specific biomarkers rather than weight alone.

Increased levels of specific fatty acid metabolites (3-hydroxylaurate, 3-hydroxyoctanoate, 3-hydroxydecanoate, 3-hydroxymyristate) and decreased levels of 1,5-anhydroglucitol (1,5-AG) and dimethylarginine (ADMA+SDMA) are associated with disease progression from insulin resistance to Type 2 Diabetes.

For individuals with obesity and insulin resistance, monitoring specific fatty acid metabolites and 1,5-AG levels may provide early warning signs of progression to Type 2 Diabetes. Decreasing 1,5-AG and increasing certain hydroxy-fatty acids are associated with this progression, suggesting these could be valuable markers for early intervention.

Marked subclinical hypothyroidism (TSH > 10 mIU/L) is significantly associated with increased odds of prevalent metabolic syndrome, but this association may be confounded by thyroid hormone replacement therapy use.

For older adults with significantly elevated TSH (>10 mIU/L), there is a higher risk of metabolic syndrome, particularly high triglycerides and low HDL. However, this risk is heavily influenced by whether the patient is taking thyroid medication. If you are not on medication, your risk profile is less clear. Regular monitoring of lipid levels is recommended for this group.

Higher serum glucose levels are positively correlated with bone mineral density in non-diabetic postmenopausal women, contradicting the assumption that hyperglycemia always reduces BMD.

In non-diabetic postmenopausal women, slightly higher glucose levels within the normal range are associated with better bone density, though this does not mean high sugar intake is beneficial.

Higher serum HDL cholesterol is associated with higher bone mineral density at the femoral trochanter and a lower risk of vertebral fractures in postmenopausal women.

Maintaining healthy lipid profiles, including HDL, may support bone health in postmenopausal women, though the mechanism is not fully understood.

Metformin use is associated with reduced cancer incidence and mortality in diabetic patients, with specific benefits observed in HER2-positive breast cancer and prostate cancer recurrence.

If you have type II diabetes, metformin is a standard treatment that may also offer protective benefits against certain cancers. Discuss with your doctor if metformin is appropriate for you, especially if you have a family history of breast or prostate cancer. Do not take metformin solely for cancer prevention if you do not have diabetes.

Administration of Meteorin-like protein (METRNL) attenuates lipid-induced inflammation and insulin resistance in skeletal muscle by activating AMPK and PPARδ signaling pathways, leading to increased fatty acid oxidation and reduced pro-inflammatory cytokine expression.

This research suggests that the metabolic benefits of exercise are partly driven by specific proteins (like METRNL) released by muscles, which directly improve insulin sensitivity and reduce inflammation. While this specific protein is not yet a commercial supplement, the finding supports the importance of resistance training and physical activity for managing metabolic health, independent of weight loss or calorie counting.

Fecal microbiota transplantation (FMT) from lean donors improves peripheral and hepatic insulin sensitivity in patients with metabolic syndrome.

For some patients with metabolic syndrome, transferring healthy gut bacteria from lean donors via FMT can improve how their body uses insulin. This is a medical procedure, not a DIY fix, and is currently an area of active research for treating metabolic disorders.

Anabolic androgenic steroids (AAS) used for bodybuilding cause a distinct phenotype of liver injury characterized by high bilirubin levels with relatively low transaminases, often leading to cholestasis and liver neoplasms.

If you are using anabolic steroids for bodybuilding, be aware that they can cause serious liver damage, including cholestasis, liver tumors, and acute liver failure. Symptoms may include jaundice (yellowing of skin/eyes) and abdominal pain. Regular liver function monitoring is crucial, and you should discuss your steroid use with a healthcare provider.

Snoring during pregnancy is associated with an increased risk of gestational diabetes mellitus (GDM), with the risk being particularly elevated in overweight women.

If you snore frequently during pregnancy, especially if you are overweight, mention it to your doctor. It may be a sign of sleep apnea, which can increase your risk of gestational diabetes.

Chronic, high-dose anabolic steroid use in weightlifters causes pathological cardiac hypertrophy, myocardial fibrosis, and increased risk of life-threatening arrhythmias and thrombosis.

If you are using high-dose anabolic steroids for bodybuilding, you are at significant risk for heart failure, blood clots in the heart, and sudden cardiac death due to arrhythmias. These risks are not just theoretical; they are documented in weightlifters. The structural damage to the heart (fibrosis and thickening) may not be fully reversible even after stopping the drugs. Medical monitoring is critical, but cessation is the only way to potentially mitigate further damage.

Cessation of anabolic steroid use can lead to partial reversal of cardiac hypertrophy and improvement in left ventricular function, though fibrosis may persist.

If you stop using anabolic steroids, your heart function (how well it pumps) and wall thickness may improve significantly within months. However, the scarring (fibrosis) inside the heart muscle may not go away. This means you are not 'cured' of the risk, but your prognosis is better than if you continued use.

Myostatin inhibition via antibody administration significantly increases muscle mass and strength in aged animal models, representing a promising therapeutic strategy for sarcopenia.

This paper highlights myostatin inhibition as a promising drug target for sarcopenia, showing significant muscle gains in aged mice. However, this is not a current consumer intervention. For now, resistance training combined with amino acid supplementation remains the best practical strategy to prevent age-related muscle loss.

Administration of growth hormone (GH) or IGF-1 reverses age-related cardiovascular deficits, including increased coronary blood flow, capillary density, and myocardial contractility, in aged animals and humans with heart failure.

If you are diagnosed with adult-onset growth hormone deficiency or have heart failure, GH replacement therapy may improve your heart's pumping ability and blood flow. However, this is a prescription medication with significant risks, including potential cancer promotion and diabetes. It is not recommended for healthy aging individuals without a clear deficiency, and long-term safety data is lacking. Consult an endocrinologist.